Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Report Earnings of $0.49 Per Share
Stock analysts are predicting that Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) will report earnings of $0.49 per share for the current quarter, according to Zacks. Eleven analysts made earnings estimates for Neurocrine Biosciences. The highest EPS estimate is $0.75 and the lowest is $0.31. Neurocrine Biosciences reported earnings of $0.43 per share in the same quarter last year, suggesting a positive year-over-year growth rate of 14%. The company is expected to release its next results on Monday, January 1.
According to Zacks, analysts expect Neurocrine Biosciences to report annual earnings of $1.86 per share for the current fiscal year, with EPS estimates ranging from $1.55 to $2.41. For the next fiscal year, analysts expect the company to post earnings of $3.40 per share, with EPS estimates ranging from $2.15 to $5.05. Zacks earnings per share averages are an average average based on a survey of sell-side research analysts who cover Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) last released its results on Wednesday, May 4. The company reported earnings per share of $0.14 for the quarter, missing the consensus estimate of $0.35 per ($0.21). The company posted revenue of $310.60 million in the quarter, compared to analyst estimates of $304.07 million. Neurocrine Biosciences posted a net margin of 5.91% and a return on equity of 5.30%. The company’s revenue for the quarter increased 31.3% year over year. During the same period last year, the company posted EPS of $0.33.
Several analysts weighed in on NBIX shares. JPMorgan Chase & Co. raised its target price on Neurocrine Biosciences from $125.00 to $126.00 and gave the company an “overweight” rating in a Monday, April 4 report. Goldman Sachs Group has downgraded Neurocrine Biosciences from a “neutral” rating to a “buy” rating and set a price target of $115.00 on the stock in a Thursday, February 24 research report. Piper Sandler downgraded Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and reduced its price target for the company from $114.00 to $94.00 in a Thursday, March 3 research report. Wedbush rephrased an “outperform” rating on Neurocrine Biosciences shares in a Thursday, April 28 research report. Finally, Zacks Investment Research upgraded Neurocrine Biosciences from a “Strong Sell” rating to a “Hold” rating in a Thursday, April 21 research report. One equity research analyst assigned the stock a sell rating, nine issued a hold rating and ten assigned the company’s stock a buy rating. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $112.13.
Neurocrine Biosciences stock traded at $5.73 during Friday trading hours, hitting $79.55. The stock had a trading volume of 1,094,739 shares, compared to an average volume of 660,754. The company has a leverage ratio of 0.27, a current ratio of 4.02 and a quick ratio of 3, 83. The stock has a market capitalization of $7.60 billion, a price-earnings ratio of 110.49 and a beta of 0.70. Neurocrine Biosciences has a 1-year low of $71.88 and a 1-year high of $108.01. The stock’s fifty-day moving average is $93.13 and its two-hundred-day moving average is $88.01.
In other news, manager Gary A. Lyons sold 15,000 shares in a trade dated Monday, April 25. The stock was sold at an average price of $92.76, for a total value of $1,391,400.00. Following the completion of the sale, the administrator now owns 208,697 shares of the company, valued at $19,358,733.72. The transaction was disclosed in a legal filing with the SEC, which is available via this link. Additionally, manager William H. Rastetter sold 10,728 shares in a trade dated Friday, April 1. The shares were sold at an average price of $94.93, for a total value of $1,018,409.04. Following the completion of the sale, the director now owns 34,022 shares of the company, valued at approximately $3,229,708.46. The disclosure of this sale can be found here. Last quarter, insiders sold 46,743 shares of the company valued at $4,232,771. Insiders hold 4.40% of the shares of the company.
Hedge funds and other institutional investors have recently changed their stakes in the company. Whittier Trust Co. increased its stake in Neurocrine Biosciences by 102.8% during the 4th quarter. Whittier Trust Co. now owns 290 shares of the company valued at $25,000 after buying 147 additional shares in the last quarter. IndexIQ Advisors LLC acquired a new stake in Neurocrine Biosciences during Q1 worth approximately $27,000. Moors & Cabot Inc. acquired a new stake in Neurocrine Biosciences during Q3 valued at approximately $30,000. KB Financial Partners LLC acquired a new stake in Neurocrine Biosciences during Q4 valued at approximately $33,000. Finally, Orion Capital Management LLC acquired a new stake in Neurocrine Biosciences during Q4 valued at approximately $34,000. Hedge funds and other institutional investors hold 93.21% of the company’s shares.
About Neurocrine Biosciences (Get a rating)
Neurocrine Biosciences, Inc. discovers, develops and markets pharmaceutical products for neurological, endocrine and psychiatric disorders. The Company’s portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids, as well as clinical programs in various therapeutic areas.
Get a Free Copy of Zacks Neurocrine Biosciences (NBIX) Research Report
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Neurocrine Biosciences Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Neurocrine Biosciences and related companies with MarketBeat.com’s FREE daily newsletter.